Last update 01 Jun 2025

Emibetuzumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-c-MET-monoclonal-antibody-Eli-Lilly, c-MET monoclonal antibody - Eli Lilly, c-MET-mAb-Eli-Lilly
+ [4]
Target
Action
inhibitors
Mechanism
c-Met inhibitors(Hepatocyte growth factor receptor inhibitors)
Originator Organization
Active Organization
Inactive Organization-
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
-Emibetuzumab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced cancerPhase 2
United States
07 Mar 2014
Fibrolamellar Hepatocellular CarcinomaPhase 2
United States
07 Mar 2014
Gastroesophageal junction adenocarcinomaPhase 2
United States
07 Mar 2014
Renal Cell CarcinomaPhase 2
United States
07 Mar 2014
stomach adenocarcinomaPhase 2
United States
07 Mar 2014
c-Met positive non-small cell lung cancerPhase 2
United States
01 Aug 2013
c-Met positive non-small cell lung cancerPhase 2
Belgium
01 Aug 2013
c-Met positive non-small cell lung cancerPhase 2
France
01 Aug 2013
c-Met positive non-small cell lung cancerPhase 2
Germany
01 Aug 2013
c-Met positive non-small cell lung cancerPhase 2
Israel
01 Aug 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
EGFR positive non-small cell lung cancer
First line
MET Overexpression | EGFR Positive
-
mgxxrnlmup(ztgvlppmje) = hmygalzjof sqrttttzkz (sjhxbdvgwv )
Positive
01 Jan 2020
mgxxrnlmup(ztgvlppmje) = fpejoxufst sqrttttzkz (sjhxbdvgwv )
Phase 1/2
Advanced cancer
MET Positive
97
wfminlsqwl(ocjlxpudmb) = Common adverse events were primarily mild or moderate and included fatigue (36.1%), peripheral edema (28.9%), and nausea (14.4%). lysbmclmom (ujsakikppl )
Positive
01 Sep 2019
Phase 2
15
zbggqmezps(qcvqkvuynb) = ofzlkvffsx ezrkxxoddn (jwqrlnzeax, 33 - 59)
Negative
01 Dec 2017
Phase 1/2
97
xrxbfxznmy(vefitpsyht) = Common possibly related AEs of all grades included dyspnea (16%) wtbhackjmz (qmsservumb )
-
01 Jul 2017
Phase 1
37
(solid tumors)
blxahgtfxg(golttpzfpi) = Twenty-three patients with solid tumors received emibetuzumab monotherapy at 20, 70, 210, 700, 1,400, and 2,000 mg and 14 non-small cell lung cancer (NSCLC) patients at 700, 1,400, and 2,000 mg in combination with erlotinib 150 mg daily. kkaqehqosm (ictqqyivld )
Positive
15 Apr 2017
Phase 2
111
yquhiyywdo(mnqcrwcjkl) = psvmruetfn dplsvhmgfz (sekelpucjc )
Positive
04 Jun 2016
yquhiyywdo(mnqcrwcjkl) = cvtnwdnapz dplsvhmgfz (sekelpucjc )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free